Additional Relevant Details Transaction would add VYXEOS™, an investigational product in development as a treatment for Acute Myeloid Leukemia (AML), to Jazz Pharmaceuticals' portfolio
U.S. regulatory submission for VYXEOS planned by end of third quarter 2016
Jazz Pharmaceuticals to host investor conference call today, May 31, 2016 at 8:30 AM EDT (1:30 PM IST)

VYXEOS is the first product candidate to demonstrate a statistically significant improvement in Overall Survival in patients with high-risk (secondary) AML1

U.S. FDA Breakthrough Therapy designation granted for VYXEOS2

U.S. FDA and European Commission Orphan Drug designation for VYXEOS for the treatment of AML

VYXEOS is an innovative product candidate based on the Celator CombiPlex® platform

Anticipated long-lived exclusivity for VYXEOS